Autozi Signs Cooperation Agreement with the Suizhou Special Purpose Vehicle Chamber of Commerce, Targeting US$2 Billion and Forging Another Major Milestone in the Company's Development History.
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
